Royal Pharmaceuticals

Manufacturer Details

There are currently no manufacturer details available.

Share This Page

Royal Pharmaceuticals Drugs

  • Pediapred (Prednisolone Sodium Phosphate) Solution [Royal Pharmaceuticals]

    Pediapred

    Pediapred (Prednisolone Sodium Phosphate) Solution [Royal Pharmaceuticals]

    The initial dosage of PEDIAPRED may vary from 5 mL to 60 mL (5 to 60 mg prednisolone base) per day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time, there is a lack of satisfactory clinical response, PEDIAPRED should be discontinued and the patient placed on other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of PEDIAPRED for a period of time consistent with the patient's condition. If after long term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

    In the treatment of acute exacerbations of multiple sclerosis, daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day or 4 to 8 mg dexamethasone every other day for one month have been shown to be effective.

    In pediatric patients, the initial dose of PEDIAPRED may vary depending on the specific disease entity being treated. The range of initial doses is 0.14 to 2 mg/kg/day in three or four divided doses (4 to 60 mg/m2bsa/day).

    The standard regimen used to treat nephrotic syndrome in pediatric patients is 60 mg/m2/day given in three divided doses for 4 weeks, followed by 4 weeks of single dose alternate-day therapy at 40 mg/m2/day.

    The National Heart, Lung, and Blood Institute (NHLBI) recommended dosing for systemic prednisone, prednisolone or methylprednisolone in children whose asthma is uncontrolled by inhaled corticosteroids and long-acting bronchodilators is 1-2 mg/kg/day in single or divided doses. It is further recommended that short course, or "burst" therapy, be continued until a child achieves a peak expiratory flow rate of 80% of his or her personal best or symptoms resolve. This usually requires 3 to 10 days of treatment, although it can take longer. There is no evidence that tapering the dose after improvement will prevent a relapse.

    For the purpose of comparison, the following is the equivalent milligram dosage of the various glucocorticoids:

    Cortisone, 25 Triamcinolone, 4 Hydrocortisone, 20 Paramethasone, 2 Prednisolone, 5 Betamethasone, 0.75 Prednisone, 5 Dexamethasone, 0.75 Methylprednisolone, 4

    These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.

  • Derma-smoothe/fs (Fluocinolone Acetonide) Oil [Royal Pharmaceuticals]

    Derma-smoothefs

    Derma-smoothe/fs (Fluocinolone Acetonide) Oil [Royal Pharmaceuticals]

    Derma-Smoothe/FS® is not for oral, ophthalmic, or intravaginal use.

    The dosing of Derma-Smoothe/FS® is different for adult and pediatric patients.

    2.1 Adult Patients with Atopic Dermatitis

    Apply Derma-Smoothe/FS® as a thin film to the affected areas three times daily.

    2.2 Pediatric Patients with Atopic Dermatitis

    Moisten skin and apply Derma-Smoothe/FS® as a thin film to the affected areas twice daily for up to four weeks.

  • Derma-smoothe/fs (Fluocinolone Acetonide) Oil [Royal Pharmaceuticals]

    Derma-smoothefs

    Derma-smoothe/fs (Fluocinolone Acetonide) Oil [Royal Pharmaceuticals]

    Derma-Smoothe/FS® for scalp psoriasis in adults (Scalp Oil):

    For the treatment of scalp psoriasis, wet or dampen hair and scalp thoroughly. Apply a thin film of Derma-Smoothe/FS® on the scalp, massage well and cover scalp with the supplied shower cap. Leave on overnight or for a minimum of 4 hours before washing off. Wash hair with regular shampoo and rinse thoroughly.

  • Dermotic (Fluocinolone Acetonide) Oil [Royal Pharmaceuticals]

    Dermotic

    Dermotic (Fluocinolone Acetonide) Oil [Royal Pharmaceuticals]

    For the treatment of chronic eczematous external otitis, using the supplied ear-dropper, apply 5 drops of DermOtic® Oil into the affected ear. To apply, tilt head to one side so that the ear is facing up. Then gently pull the ear lobe backward and upward and apply 5 drops of DermOtic® Oil into the ear. Keep head tilted for about a minute to allow DermOtic® Oil to penetrate lower into the ear canal. Gently pat excess material dripping out of the ear using a clean cotton ball. Follow these instructions twice each day for 7 to 14 days.